Market Cap | 10.07M | P/E | - | EPS this Y | 71.00% | Ern Qtrly Grth | - |
Income | -17.23M | Forward P/E | -0.48 | EPS next Y | 54.80% | 50D Avg Chg | -8.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -1.00% |
Dividend | N/A | Price/Book | 0.66 | EPS next 5Y | - | 52W High Chg | -51.00% |
Recommedations | 2.00 | Quick Ratio | 0.35 | Shares Outstanding | 4.89M | 52W Low Chg | 41.00% |
Insider Own | 6.16% | ROA | -91.42% | Shares Float | 4.59M | Beta | 1.13 |
Inst Own | 0.50% | ROE | -362.29% | Shares Shorted/Prior | 523.19K/268.40K | Price | 0.86 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 33,508 | Target Price | 3.00 |
Oper. Margin | - | Earnings Date | - | Volume | 26,747 | Change | -5.44% |
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain. The company's preclinical stage product candidates also comprise AnQlar, an anti-viral barrier to prevent or reduce the risk or the intensity of viral infections in humans, including influenza and SARS-CoV-2; and NobrXiol, an investigational formulation to be delivered via the nasal route to enhance cannabidiol transport to the brain. Virpax Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Berwyn, Pennsylvania.
Maxim Group | Buy | Jul 19, 24 |
Maxim Group | Hold | May 22, 24 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Sendrow Jerrold | Director Director | May 24 | Buy | 1.29 | 4,500 | 5,805 | 9,006 | 05/26/22 |
Mack Anthony P. | Chief Executive Offi.. Chief Executive Officer | May 18 | Buy | 1.34 | 75,750 | 101,505 | 252,562 | 05/20/22 |
Floyd Eric | Director Director | May 18 | Buy | 1.3635 | 4,479 | 6,107 | 8,018 | 05/20/22 |